1. Home
  2. MAIA vs KOSS Comparison

MAIA vs KOSS Comparison

Compare MAIA & KOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • KOSS
  • Stock Information
  • Founded
  • MAIA 2018
  • KOSS 1953
  • Country
  • MAIA United States
  • KOSS United States
  • Employees
  • MAIA N/A
  • KOSS N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • KOSS Consumer Electronics/Appliances
  • Sector
  • MAIA Health Care
  • KOSS Consumer Staples
  • Exchange
  • MAIA Nasdaq
  • KOSS Nasdaq
  • Market Cap
  • MAIA 46.7M
  • KOSS 59.3M
  • IPO Year
  • MAIA 2022
  • KOSS N/A
  • Fundamental
  • Price
  • MAIA $1.90
  • KOSS $5.25
  • Analyst Decision
  • MAIA
  • KOSS
  • Analyst Count
  • MAIA 0
  • KOSS 0
  • Target Price
  • MAIA N/A
  • KOSS N/A
  • AVG Volume (30 Days)
  • MAIA 540.7K
  • KOSS 91.8K
  • Earning Date
  • MAIA 08-08-2025
  • KOSS 05-08-2025
  • Dividend Yield
  • MAIA N/A
  • KOSS N/A
  • EPS Growth
  • MAIA N/A
  • KOSS N/A
  • EPS
  • MAIA N/A
  • KOSS N/A
  • Revenue
  • MAIA N/A
  • KOSS $12,433,361.00
  • Revenue This Year
  • MAIA N/A
  • KOSS N/A
  • Revenue Next Year
  • MAIA N/A
  • KOSS N/A
  • P/E Ratio
  • MAIA N/A
  • KOSS N/A
  • Revenue Growth
  • MAIA N/A
  • KOSS N/A
  • 52 Week Low
  • MAIA $1.40
  • KOSS $4.00
  • 52 Week High
  • MAIA $4.24
  • KOSS $18.73
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 56.86
  • KOSS 50.94
  • Support Level
  • MAIA $1.60
  • KOSS $4.83
  • Resistance Level
  • MAIA $2.03
  • KOSS $5.10
  • Average True Range (ATR)
  • MAIA 0.12
  • KOSS 0.33
  • MACD
  • MAIA 0.02
  • KOSS 0.00
  • Stochastic Oscillator
  • MAIA 69.77
  • KOSS 55.36

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About KOSS Koss Corporation

Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones.

Share on Social Networks: